Novartis Adjusts Manufacturing of Breast Cancer Drug Ribociclib
By Pierre Bertrand
Novartis said it is making manufacturing adjustments for its cancer drug ribociclib and has paused taking on new patients in studies involving the treatment in order to ensure it meets the latest regulatory guidance.
The adjustments are being made to meet new early-breast-cancer treatment standards by the end of the second quarter, following regulatory guidance on the intake of nitrosamines in medications, the Swiss pharmaceutical company said late Tuesday.
Nitrosamines are chemicals classed as probable carcinogens in humans, according to the European Medicines Agency's website.
Novartis said the change doesn't affect patient use or commercial supply of Kisqali, the brand name for the cancer treatment, which is approved for metastatic breast cancer.
The company has paused the enrollment of new patients in studies involving the drug for early breast cancer, it said.
Regulatory review of ribociclib for the treatment early breast cancer is expected to proceed as planned, Novartis said.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
April 10, 2024 02:02 ET (06:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month